THE FEATURES OF THE COURSE OF HBV INFECTION DURING ANTIVIRAL THERAPY


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Objective. To determine the features of the course of chronic hepatitis B in patients receiving and not receiving antiviral therapy (AVT). Subjects and methods. Seventy HBsAg-positive patients were followed up who had a disease duration from 1 to 15 years; of them there were 24 (34.3%) patients who received AVT with nucleoside analogues (NAs) and 46 (65.7%) who did not receive treatment. Results. During the first visit, the duration of HBsAg release was less than 5 years in 57% of the patients. The number of patients with a duration of HBsAg release for more than 20 years coincided with that of patients (11 %) with severe fibrosis (F3-F4), which was evidenced by fibroelastometry using a FibroScan. HBeAg-negative HBV infection was identified in 86% of the patients; and the initial stage of fibrosis was detected in 83%. AVT was initiated, regardless of the stage of fibrosis, more often in patients aged 41-60 years (in 41.7% of cases) with a viral load of 5 logs. Conclusion. Less than half of the patients who started taking NAs remained adherent to therapy. At the same time, the stage of liver fibrosis decreased in patients receiving AVT, which may suggest that NAs have an anti-fibrotic effect.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Khadizhat OMAROVA

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: omarova71@inbox;ru
Cand. Med. Sci., Researcher, Clinical Department of Infectious Diseases Moscow, Russia

Vera MAKASHOVA

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: veramakashova@yandex.ru
Professor, MD, Leading Researcher Moscow, Russia

Zhanna PONEZHEVA

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: doktoiim@mail.ru
MD, Head, Clinical Department of Infectious Diseases Moscow, Russia

Әдебиет тізімі

  1. WHO. Global Hepatitis Report 2017. Geneva, Switzerland. World Health Organization, 2017. https://apps.who.rnt/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf
  2. Fattovich G., Bertoletti F., Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J. Hepatol. 2008; 48, 335-52. doi: 10.1016/j.jhep.2007.11.011
  3. MacLachlan J.H.,Cowie B.C. Hepatitis B virus epidemiology. Cold Spring Harb. Perspect. Med. 2015; 5(5): a021410. doi: 10.1101/ cshperspect. a021410
  4. Ющук Н.Д., Климова Е.А., Знойко О.О., Кареткина Г.Н., Максимов С.Л., Маев И.В. Вирусные гепатиты. Клиника, диагностика, лечение. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2015. 302 с.
  5. Абдурахманов Д.Т. Хронический гепатит В и D. М.: ГЭОТАР-Медиа, 2010. 286 с.
  6. Weinbaum C., Williams I., Mast E., Wang S.A., Finelli L., Wasley A. et al. Recommendations for identication and public health manage-ment of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep. 2008; 57: 1-20.
  7. European Association for the Study ofthe Liver. EASL Clinical Practice Guidelines on the management of chronic hepatitis В virus infection. J. Hepatol. 2017; 67(2): 370-98. doi: 10.1016/j.jhep.2017.03.021
  8. Chou R., Dana T., Bougatsos S., Blazina I., Khangura J., Zakher B. Screening for hepatitis B virus infection in adolescents and adults: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann.Intern. Med. 2014; 161: 31-45. doi: 10.7326/ M13-2837
  9. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., Lok A.S.F. Management of hepatitis B: Summary of a clinical research workshop. Hepatology 2007; 45(4): 1056-75. doi: 10.1002/hep.21627
  10. Sweetman S., ed. Martindale: the complete drug reference (online version), 37th edition, 2011. http://www.pharmpress.com/product/ MC_MART/ martindale-the-complete-drug-reference
  11. Terrault N.A., Lok A.S., McMahon B.J., Chang K.-M., Hwang J/P., Jonas M.M. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67(4): 1560-99. doi: 10.1002/hep.29800
  12. Schiff E.R., Lee S.S., Chao Y.C., You-Chen Chao, Seung Kew Yoon et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin. Gastroenterol. Hepatol. 2011; 9(3): 274-6. DOI: 10.1016/j. cgh.2010.11.040
  13. Yeo Y.H., Ho H.J., Yang H.I., Tseng T.C., Hosaka T., Trinh H.N. et al. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. Gastroenterology 2019; 156(3): 635-646.e9. doi: 10.1053/j.gastro.2018. 10.027
  14. Chu C.M., Liaw Y.F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45(5): 1187-92. doi: 10.1002/hep.21612
  15. Okada M., Enomoto M., Kawada N.,Nguyen M.N. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Expert Rev. Gastroenterol. Hepatol. 2017; 11: 1095-104. doi: 10.1080/17474124. 2017. 1361822
  16. Marcellin P., Gane E., Buti M., Afdhal N., Sievert W., Jacobson I.M. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381(9865): 468-75. DOI: 10.1016/ S0140-6736(12)61425-1
  17. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. European Association for the Study of the Liver. J Hepatol 2017; 67 (2): 370-398. doi: 10.1016/j.jhep.2017.03.021

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2022

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>